EH3
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. … Read more
EH3 - Asset Resilience Ratio
EH3 (EH3) has an Asset Resilience Ratio of 24.82% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how EH3's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down EH3's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €163.78 Million | 24.82% |
| Total Liquid Assets | €163.78 Million | 24.82% |
Asset Resilience Insights
- Good Liquidity Position: EH3 maintains a healthy 24.82% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
EH3 Industry Peers by Asset Resilience Ratio
Compare EH3's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
PINK:NVSEF |
Drug Manufacturers - General | 0.13% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 7.18% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
Annual Asset Resilience Ratio for EH3 (2021–2024)
The table below shows the annual Asset Resilience Ratio data for EH3.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 25.27% | €173.18 Million | €685.35 Million | +10.67pp |
| 2023-12-31 | 14.60% | €121.41 Million | €831.68 Million | +4.25pp |
| 2022-12-31 | 10.35% | €91.69 Million | €886.18 Million | -11.62pp |
| 2021-12-31 | 21.97% | €234.67 Million | €1.07 Billion | -- |